Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 9024 results

  1. Budesonide oral suspension for inducing and maintaining remission of eosinophilic oesophagitis in people 2 to 17 years [ID6761]

    Awaiting development Reference number: GID-TA12464 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    Awaiting development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    Awaiting development

  3. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Palbociclib with anti-HER2 therapy and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    Awaiting development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Diabetic foot problems: prevention and management - topical wound oxygen therapy for diabetic foot ulcers

    Awaiting development Reference number: GID-NG10552 Expected publication date: TBC

    NICE guideline
    Awaiting development

  6. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 4 June 2026.

    Technology appraisal guidance
    In consultation

  7. Epilepsies in children, young people and adults: draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 27 May 2026.

    NICE guideline
    In consultation

  8. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    In development Reference number: GID-TA11025 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  9. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders

    In development Reference number: GID-HTG10174 Expected publication date: TBC

    HealthTech guidance
    In development

  11. Renal sympathetic denervation for resistant hypertension

    In development Reference number: GID-HTG10527 Expected publication date: TBC

    HealthTech guidance
    In development

  12. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    In development Reference number: GID-TA11886 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  13. Thermocoagulation for the treatment of piles and anal fistula

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Aggressive behaviour in people receiving NHS or social care: prevention and management

    In development Reference number: GID-NG10432 Expected publication date:  28 January 2027

    NICE guideline
    In development

  15. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development